Trial Profile

An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sevasemten (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions
Acronyms MESA
Sponsors Edgewise Therapeutics

Most Recent Events

28 Oct 2026 This trial is active no longer recruiting in Denmark,Netherlands,Italy,Spain ,Belgium ,Germany and France.
06 May 2026 Planned End Date changed from 1 Aug 2029 to 1 Feb 2031.
06 May 2026 Planned primary completion date changed from 1 Aug 2029 to 1 Feb 2031.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com